ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,618.26
      -0.29%
      US Tech 100
      19,180.40
      1.71%
      Dow Jones
      41,503.10
      -0.25%
      Brent Oil
      73.95
      2.17%
      Bitcoin
      62,094.46
      0.69%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Histogenics Corporation (HSGX) Quote

      Histogenics Corporation

      Histogenics Corporation (HSGX)

      NASDAQ
      0.162
      0.00
      (0.00%)
      Closed September 18 4:00PM
      Delayed by 15 minutes
      0.162
      0.00
      ( 0.00% )
      Pre Market: 8:00PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      0.162
      Bid
      0.164
      Ask
      0.166
      Volume
      -
      0.00 Day's Range 0.00
      0.00 52 Week Range 0.00
      Market Cap
      41.553M
      Previous Close
      0.162
      Open
      -
      Last Trade
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      256,502,000
      Dividend Yield
      -
      PE Ratio
      -4.55
      Earnings Per Share (EPS)
      -0.25
      Revenue
      6.04M
      Net Profit
      -63.08M

      About Histogenics Corporation

      Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is an tissue implant that utilizes various aspects of regenerative medicine platform to tre... Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is an tissue implant that utilizes various aspects of regenerative medicine platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Histogenics operates in two geographic regions: The United States (Massachusetts) and Israel (Tel Aviv). Regenerative medicine technologies encompass a variety of therapeutic approaches, including tissue engineering, cell-based therapies, gene therapy, small molecules and biologics, stem cells and biobanking. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Ortho,prosth,surg Appl,suply
      Website
      ocugen.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      2020

      Ask ADVFN Intelligence (AI)

      HSGX Latest News

      More News

      FeaturedElement79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership

      18 hours ago

      Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

      BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan...

      November 21 2019
      GlobeNewswire Inc.

      Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting

      BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen...

      September 26 2019
      GlobeNewswire Inc.

      Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019

      BOSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any...

      September 12 2019
      GlobeNewswire Inc.

      Histogenics Corporation Announces Intent to Convene and Adjourn Its Special Meeting

      BOSTON, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting...

      September 11 2019
      GlobeNewswire Inc.

      Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel...

      BOSTON, Mass. and MALVERN, Penn., April 08, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused...

      April 08 2019
      GlobeNewswire Inc.

      Jonathan Lieber Joins Danforth Advisors as Managing Director

      SOMERVILLE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and...

      February 12 2019
      GlobeNewswire Inc.

      Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway

      WALTHAM, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the...

      December 21 2018
      GlobeNewswire Inc.

      Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

      WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...

      November 29 2018
      GlobeNewswire Inc.

      Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results

      WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to...

      November 08 2018
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000CS
      40000000CS
      120000000CS
      260000000CS
      520000000CS
      1560000000CS
      2600000000CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ZEOZeo Energy Corporation
      $ 4.76
      (317.54%)
      		631.91k
      XCURExicure Inc
      $ 7.03
      (206.99%)
      		1.43M
      VEROVenus Concept Inc
      $ 0.9219
      (83.46%)
      		1.64M
      TBIOTelesis Bio Inc
      $ 1.74
      (27.94%)
      		29.79k
      SPISPI Energy Company Ltd
      $ 0.4979
      (27.57%)
      		3.8k
      PGNYProgyny Inc
      $ 18.75
      (-23.28%)
      		14.1k
      VEEAVeea Inc
      $ 10.30
      (-15.92%)
      		9.19k
      WBUYWeBuy Global Ltd
      $ 0.1552
      (-15.79%)
      		194.58k
      RNAZTransCode Therapeutics Inc
      $ 0.3064
      (-12.46%)
      		6.32k
      ALLRAllarity Therapeutics Inc
      $ 2.08
      (-9.57%)
      		4.3k
      FRGTFreight Technologies Inc
      $ 0.155
      (25.10%)
      		6.81M
      VEROVenus Concept Inc
      $ 0.9219
      (83.46%)
      		1.64M
      XCURExicure Inc
      $ 7.03
      (206.99%)
      		1.43M
      SQQQProShares UltraPro Short QQQ
      $ 7.96
      (-5.24%)
      		1.06M
      EJHE Home Household Service Holdings Ltd
      $ 0.112
      (5.66%)
      		900.07k

      Discussion

      View Full Feed
      falkus951 falkus951 4 minutes ago
      $LUXH 1:00 AM PST VOLUME TRADING UP% pre market

      CEO with STRONG hotel management exp bought shares of stock last month. + NO R/S. He knows something
      1. Insider Purchase http://openinsider.com/search?q=luxh
      2. https://stockcharts.com/sc3/ui/?s=LUXH&id=p07205851717
      LUXH
      RickNagra RickNagra 5 minutes ago
      Oh wow. I sm exactly expecting a massive super duper big win from the team and the players. No doubt Ron is a real person or even a politician or a genius. He knows everything. A literal legend and a great leader. Everyone should raise their glass to the world Ron. Please allow me to share my
      GNCP
      Ms Labonte Ms Labonte 5 minutes ago
      Going to the next level penny flipper$$$ .50 coming today… buy you all out ….
      RNAZ
      falkus951 falkus951 5 minutes ago
      $LUXH 1:00 AM PST VOLUME TRADING UP% pre market

      CEO with STRONG hotel management exp bought shares of stock last month. + NO R/S. He knows something
      1. Insider Purchase http://openinsider.com/search?q=luxh
      2. https://stockcharts.com/sc3/ui/?s=LUXH&id=p07205851717
      LUXH
      Ms Labonte Ms Labonte 6 minutes ago
      My pimp$ got their eye$ on you flipper$$$$
      RNAZ
      tw0122 tw0122 8 minutes ago
      $28 keep on pumping PPT $30 closer
      SVIX
      tw0122 tw0122 9 minutes ago
      Told you $70 coming PPT team pumping markets hard early on
      TQQQ
      tw0122 tw0122 12 minutes ago
      TBIO 3.80 + 180% push it more honest hedge funds we luv it
      TBIO
      tw0122 tw0122 13 minutes ago
      Missing out on ZEO TBIO and FRGT wake up lol
      FRGT TBIO ZEO
      tw0122 tw0122 14 minutes ago
      Pump it more $3.20 + 120% now. I luv Gary Gensler
      TBIO
      jrsh jrsh 15 minutes ago
      Yep, unbelievable, they just don't get it that announcements without following through are undermining trust and confidence big time and it would be much better to hold back until being sure!!!

      They still owe us several game changers, great news ahead and other information!!!
      NSAV
      Ms Labonte Ms Labonte 15 minutes ago
      .50 on radar $creen today… lookout for leg$$ $trait up$$$$
      CREEN TRAIT
      dennisdave dennisdave 17 minutes ago
      Yes
      And at ASM they said they haven’t even started the process of writing the pricing model to submit for appraisal as far as I remember and no timeline was given ( unless you consider several months as a timeline )

      I know that is one reason we have tanked 32% since then. But t
      ASM NWBO
      snow snow 20 minutes ago
      I listened to part of the interview. I was not impressed by the performance of management. What is positive is that the company will try to expand the sms business that has better profit margins than the voice business. If I did not misunderstand the hope is to improve the bottom line by two million
      IQST
      toohot toohot 20 minutes ago
      Everything at BIEL is progressing. Don’t let the egg sucking dogs detour your beliefs!





      BUY $BIEL$
      BIEL
      tw0122 tw0122 21 minutes ago
      Zeo $6 + 400% let’s go
      ZEO
      tw0122 tw0122 21 minutes ago
      zeo to the moon $5 + 300% pump it baby
      ZEO
      Money hunt Money hunt 22 minutes ago
      No reverse news coming !! partnership agreement with IBM in the works!!!
      FOXO
      tw0122 tw0122 23 minutes ago
      .19 +’53% we love Bayer
      FRGT
      tw0122 tw0122 24 minutes ago
      Pump it .18s for a 40% gain
      FRGT
      tw0122 tw0122 26 minutes ago
      NVDL $54 those $51s and $52s nice 6% flip at premarket open Yellen and Powell
      Pump the markets at play enjoy
      NVDA

      Your Recent History

      NASDAQ
      HSGX
      Histogenics
      USOTC
      ATIW
      ATI Networks (CE)
      Delayed Upgrade Clock